WOA Signs 12 NDAs as German Facility Wind-Down Begins, Cash at $1.27M

Strategic Shift to Contract Manufacturing

Wide Open Agriculture (ASX:WOA) is steering away from its owner-operated production in Germany, opting instead for a contract manufacturing model designed to slash costs and capital requirements. This four-stage "Building Better Economics" strategy was unveiled shortly after the quarter ended, marking a decisive move to reshape the company's manufacturing footprint. The German facility, which served as a proof of concept and helped secure key regulatory approvals including China market access, is being wound down due to high energy costs and inefficiencies inherent in its scale and design.

The new approach targets an initial production volume of 500 to 1,000 tonnes per annum of lupin protein isolate through third-party contract manufacturers (CMOs), aiming to deliver improved unit economics and faster scale-up potential. This pivot allows WOA to concentrate on its core intellectual property; full value extraction from whole lupin seed; while leveraging external manufacturing expertise.

German Facility Wind-Down and Contract Manufacturing Progress

WOA has completed remaining contract manufacturing orders for pea protein at the German site and concluded tolling negotiations. A production trial using an alternative lupin protein processing method has validated the transition plan. Post-quarter, the company began idling the facility, exiting the lease, standing down staff, and initiating the sale of surplus equipment alongside administrative steps to liquidate the entity.

On the contract manufacturing front, WOA has identified about 90 potential CMOs, signed 12 non-disclosure agreements, and issued several term sheets. While no binding agreements are yet in place, the structured stage-gate process aims to protect WOA’s IP and expedite the shift. This measured approach underscores the uncertainty inherent in securing suitable manufacturing partners but reflects tangible progress toward the new model.

Simplified Royalty Structure Enhances Financial Clarity

In a move to support more straightforward financial modelling and competitive pricing, WOA renegotiated its royalty terms with Curtin University. The previous tiered royalty structure has been replaced with a flat 3.5% rate on net sales, alongside a reduced minimum annual royalty of $50,000. This adjustment lowers the effective royalty burden at scale, aligning incentives between WOA and Curtin University as the company aims to expand production volumes.

Board Renewal and Technology Development

The company refreshed its board with the appointments of Justin Brown as Non-Executive Chairman and Jack Guidry as Non-Executive Director, joining continuing director Matthew Skinner. This renewal brings fresh commercial and capital markets expertise, supporting WOA’s ambitious commercialisation plans.

WOA also advanced its intellectual property development, focusing on alternative processing techniques to enhance manufacturing flexibility and cost efficiency with CMOs. Collaborative work with Curtin University and third-party equipment manufacturers continues to underpin these efforts.

Long-Term Production Plans and Financial Position

While near-term efforts focus on contract manufacturing, WOA is progressing a Pre-Feasibility Study for a large-scale lupin ingredient facility targeting over 10,000 tonnes per annum. The study, now in final draft under board review, informs discussions with potential CMOs and partners but remains contingent on future funding and approvals.

Financially, WOA ended the quarter with $1.274 million in cash, supported by a A$1.69 million R&D tax rebate reflecting its ongoing innovation in lupin protein technology. The company has enacted cash burn reduction measures including limiting marketing and R&D spend and deferring portions of executive and board remuneration.